ResearchMoz added Latest Research Report titled " Safinamide (Parkinsons Disease) - Forecast and Market Analysis to 2022 " to it's Large Report database.
Safinamide (Parkinsons Disease) - Forecast and Market Analysis to 2022
Summary
Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=197521
In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug.
Scope
- Overview of Parkinsons disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Safinamide for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Disease Management 21
4.1 Overview 21
4.1.1 Diagnosis - The UK Brain Bank Criteria 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.2 Treatment Synopsis 25
4.2.1 Dopaminergic Therapy Classes 25
4.2.2 Treatment of Parkinsons Disease by Stage 27
4.2.3 Other Treatment Options 30
4.3 Parkinsons Disease Assessment Scales 30
4.3.1 Unified Parkinsons Disease Rating Scale (UPDRS) 31
4.3.2 Hoehn and Yahr Clinical Staging 33
4.3.3 Other Clinical Assessments 34
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Safinamide (Parkinsons Disease) - Forecast and Market Analysis to 2022
Summary
Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=197521
In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug.
Scope
- Overview of Parkinsons disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Safinamide for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Disease Management 21
4.1 Overview 21
4.1.1 Diagnosis - The UK Brain Bank Criteria 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.2 Treatment Synopsis 25
4.2.1 Dopaminergic Therapy Classes 25
4.2.2 Treatment of Parkinsons Disease by Stage 27
4.2.3 Other Treatment Options 30
4.3 Parkinsons Disease Assessment Scales 30
4.3.1 Unified Parkinsons Disease Rating Scale (UPDRS) 31
4.3.2 Hoehn and Yahr Clinical Staging 33
4.3.3 Other Clinical Assessments 34
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment